ArticleEJNMMI research2025
[
Article in EJNMMI research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundCongenital hyperinsulinism (CHI) is a life threatening disease. Localization of affected intrapancreatic beta cells responsible for focal forms during surgery can be challenging. In this study we investigated a new radioguided surgical (RGS) approach using [68Ga]Exendin to facilitate intraoperative focus detection. All patients were scanned initially with [18F]-DOPA-PET followed by [68Ga]Exendin PET to differentiate between focal and non-focal forms. Focal CHI patients were then operated. At the beginning of standard surgical dissection of the pancreas in CHI patients (n = 12), 46 MBq of [68Ga]Exendin were injected intravenously. Intrapancreatic localization of the foci was determined by using a hand-held positron- and gamma-radiation probe. RGS was carried out as enucleation of CHI foci. Duration of surgery (defined as the time lapse from first incision until final suture placement) for RGS was compared with historical data of patients operated on without RGS. Long term follow-up data on euglycemic control were retrieved from patient´s medical files.
results[18F]-DOPA- and [68Ga]Exendin PET findings were concordant in all patients. Overall, 12 CHI patients underwent RGS. In 11/12 children (92%) the CHI foci localized pre-operatively by [68Ga]Exendin PET could be detected intraoperatively using the hand-held positron probe. There was a high correlation between PET imaging results and positron probe findings in respect to the identification of the affected pancreatic region. One pancreatic lesion in close proximity to the left kidney could not be detected by the positron probe. Histopathology confirmed all resected lesions as CHI foci. Intraoperatively, the signal of the focus was > 10 times higher than the signal of normal adjacent pancreatic tissue. Median duration of surgery was 4.7 h (CI 3.5–6.7) in RGS patients compared to 5.5 h (CI 4-6.7) in patients undergoing surgery without radio guidance. All patients remained euglycemic after surgery (median follow-up 3 years, range 2 to 4.5).
conclusionsIn this study, we demonstrated the use of [68Ga]Exendin for intraoperative localization of intrapancreatic CHI foci. RGS facilitates localization of intrapancreatic CHI focus and thus potentially reduces duration of surgery and perioperative complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.